NCT06730750View on ClinicalTrials.gov

A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

February 12, 2025

Primary Completion Date

September 5, 2026

Study Completion Date

December 9, 2029

Conditions
Advanced Solid Tumors
Interventions
DRUG

BMS-986490

Specified dose on specified days.

DRUG

Bevacizumab

Specified dose on specified days.

Trial Locations (6)

4215

RECRUITING

Tasman Oncology Research, Southport

15232

NOT_YET_RECRUITING

Local Institution - 0006, Pittsburgh

49546

RECRUITING

START Midwest, Grand Rapids

90033

RECRUITING

USC/Norris Comprehensive Cancer Center, Los Angeles

07601

RECRUITING

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

M5G 2M9

RECRUITING

Princess Margaret Cancer Centre, Toronto

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06730750 - A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter